According to
National Institute of Environment Health Sciences, a biomarker is an objective the measure that captures physiologic, pathologic, or anatomic characteristics of a
person to understand the state of being, more precisely a warning system of the
body. With the recent technological advancements in the field of mobile and
digitally connected technologies, the concept of biomarkers has diverged into a
new class altogether called digital biomarkers. This new emerging concept of
digital biomarkers has found implications in both clinical trials as well as
clinical care. The technology enables the collection of consumers generated
physiological and behavioral data with the help of digitally connected tools
such as wearable, implantable, and ingestible devices and sensors.
The hype around
wearable technology has cleared and the uptake of the same has significantly
skyrocketed in the past five years. According to a report from the European
Commission, the shipment of wearables is expected to increase to $150 billion
by 2026 from the estimated level of $30 billion in 2016. The growth in this
market can be attributed to increasing consumer demand for user-friendly and
self-monitoring devices, the surge in the prevalence of chronic diseases, and
increasing health awareness. The market is also driven by technological
advancements and attractive product features such as smartphone app connectivity.
The use of
wearables in clinical research have immense potential to convert longitudinal
biometric data sets into meaningful and actionable intelligence that can be
used as a digital therapeutic to treat medical conditions. The number of
clinical trials conducted using wearable devices was consistent during the
period of 2008 to 2018, i.e. 5-12 trials annually. However, the number surged
significantly in the year 2016 and 2017, with 27 and 32 trials commencing each
year respectively using mobile devices. The primary reason for the spike in
2016 and 2017 were found to be a considerable surge in the sponsorship for these
studies.
The digital
biomarkers market can be categorized on the basis of environment a digital
biomarker is being used in. As of 2018, a clinical setting holds the largest
market share wherein a clinician monitors/detects/ diagnoses a specific
condition of a patient with the help of digital biomarkers. On the other hand,
digital biomarkers also require clinical validation before they can be
recommended to patients, hence, digital technology vendors are increasingly
collaborating with biopharma companies to validate their claims and products.
This segment is expected to account for approximately 91% of the overall
digital biomarkers market from a current share of 7.76% (2018).
As claimed by Stanford Medical, It's indeed the ONLY reason this country's women get to live 10 years more and weigh an average of 42 lbs less than we do.
ReplyDelete(And really, it has absolutely NOTHING to do with genetics or some secret-exercise and really, EVERYTHING around "how" they are eating.)
P.S, What I said is "HOW", and not "WHAT"...
CLICK this link to discover if this short questionnaire can help you release your real weight loss potential